2009
DOI: 10.1016/j.lfs.2009.08.016
|View full text |Cite
|
Sign up to set email alerts
|

Do immunotherapy and ß cell replacement play a synergistic role in the treatment of type 1 diabetes?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(8 citation statements)
references
References 83 publications
0
8
0
Order By: Relevance
“…However, it is worth mentioning that the expression of MHC I and MHC II in undifferentiated MSCs could be proportionally increased with the differentiation extent of MSCs. 123 The therapeutic benefit of MSC transplantation in various disorders characterized by cell injury or cell loss are shown in some recent studies such as myocardial infarction, 124,125 traumatic brain injury, [126][127][128] Parkinson's disease, 129 type 1 diabetes, 94,130,131 and liver disease. 132 Lately, with the discovery of MSCs' tumor tropism, much interest is dedicated to determining the role MSCs could have in cancer therapy.…”
Section: Mscs In Therapeuticsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, it is worth mentioning that the expression of MHC I and MHC II in undifferentiated MSCs could be proportionally increased with the differentiation extent of MSCs. 123 The therapeutic benefit of MSC transplantation in various disorders characterized by cell injury or cell loss are shown in some recent studies such as myocardial infarction, 124,125 traumatic brain injury, [126][127][128] Parkinson's disease, 129 type 1 diabetes, 94,130,131 and liver disease. 132 Lately, with the discovery of MSCs' tumor tropism, much interest is dedicated to determining the role MSCs could have in cancer therapy.…”
Section: Mscs In Therapeuticsmentioning
confidence: 99%
“…161 In addition, inhibition of lymphocyte proliferation and suppression of the immune function of effector T lymphocytes (T eff ), such as: CD4 þ and CD8 þ T cells, B cells, and natural killer cells have been observed by MSCs. 131,162 The interaction and influence of MSCs on the immune system has proven to be more complex than previously thought, and it appears that this could be attributed to direct cell interactions between MSCs and other soluble factors that are released from MSCs.…”
Section: Immunosuppressionmentioning
confidence: 99%
“…In addition, the immunosuppressive capacity of MSC may also be mediated by the secretion of soluble factors, and by the induction of T-cell anergy and regulatory T-cells (Tregs), with important consequences for treatment, e.g. improvement of current tolerization strategies using anti-CD3 antibodies [20,21]. Recent studies demonstrated that the secretion of key soluble factors is not a constitutive process: secretion is often a consequence of cross-talk between MSC and T-lymphocytes, the latter being able to trigger this de novo expression [22].…”
Section: Msc Immnomodulatory Properties In Vitro and In Vivomentioning
confidence: 99%
“…The mechanisms underlying immunomodulation by MSCs are different: suppression of T cell proliferation and dendritic cell differentiation [42], inhibition of B-cells [43], and natural killer cells (NK) proliferation [44], induction of T cells anergy and stimulation of regulatory T cells (CD4+CD25+FoxP3+ T regs) [45,46].…”
Section: Immunomodulatory Properties and Tolerogenic Activity By Mscsmentioning
confidence: 99%